A rapid method for estimation of baculovirus titer based on viable cell sizeJANAKIRAMAN, Vasantharajan; FORREST, William F; CHOW, Bernard et al.Journal of virological methods. 2006, Vol 132, Num 1-2, pp 48-58, issn 0166-0934, 11 p.Article

ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damageDORNAN, David; SHIMIZU, Harumi; MAH, Angie et al.Science (Washington, D.C.). 2006, Vol 313, Num 5790, pp 1122-1126, issn 0036-8075, 5 p.Article

Bcl10 activates the NF-κB pathway through ubiquitination of NEMOZHOU, Honglin; WERTZ, Ingrid; O'ROURKE, Karen et al.Nature (London). 2004, Vol 427, Num 6970, pp 167-171, issn 0028-0836, 5 p.Article

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of OriginLAI, Albert; KHARBANDA, Samir; ELLINGSON, Benjamin M et al.Journal of clinical oncology. 2011, Vol 29, Num 34, pp 4482-4490, issn 0732-183X, 9 p.Article

The mutation spectrum revealed by paired genome sequences from a lung cancer patientLEE, William; ZHAOSHI JIANG; HA, Connie et al.Nature (London). 2010, Vol 465, Num 7297, pp 473-477, issn 0028-0836, 5 p.Article

Recurrent R-spondin fusions in colon cancerSESHAGIRI, Somasekar; STAWISKI, Eric W; GUILLORY, Joseph et al.Nature (London). 2012, Vol 488, Num 7413, pp 660-664, issn 0028-0836, 5 p.Article

Loss of the Tumor Suppressor BAP1 Causes Myeloid TransformationDEY, Anwesha; SESHASAYEE, Dhaya; JIANSHENG WU et al.Science (Washington, D.C.). 2012, Vol 337, Num 6101, pp 1541-1546, issn 0036-8075, 6 p.Article

Diverse somatic mutation patterns and pathway alterations in human cancersZHENGYAN KAN; JAISWAL, Bijay S; MOORHEAD, Martin et al.Nature (London). 2010, Vol 466, Num 7308, pp 869-873, issn 0028-0836, 5 p.Article

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerRUDIN, Charles M; DURINCK, Steffen; RIVERS, Celina Sanchez et al.Nature genetics. 2012, Vol 44, Num 10, pp 1111-1116, issn 1061-4036, 6 p.Article

Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsHOEFLICH, Klaus P; GRAY, Daniel C; MURRAY, Lesley J et al.Cancer research (Baltimore). 2006, Vol 66, Num 2, pp 999-1006, issn 0008-5472, 8 p.Article

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibEBERHARD, David A; JOHNSON, Bruce E; KLEIN, Pam et al.Journal of clinical oncology. 2005, Vol 23, Num 25, pp 5900-5909, issn 0732-183X, 10 p.Article

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signallingWERTZ, Ingrid E; O'ROURKE, Karen M; MA, Averil et al.Nature (London). 2004, Vol 430, Num 7000, pp 694-699, issn 0028-0836, 6 p.Article

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer PatientsHURVITZ, Sara A; BETTING, David J; DAMARAJU, Sambasivarao et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3478-3486, issn 1078-0432, 9 p.Article

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non―Small Cell Lung CancerWALTER, Kim; HOLCOMB, Thomas; MODRUSAN, Zora et al.Clinical cancer research (Print). 2012, Vol 18, Num 8, pp 2360-2373, issn 1078-0432, 14 p.Article

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthHATZIVASSILIOU, Georgia; KYUNG SONG; MORALES, Tony et al.Nature (London). 2010, Vol 464, Num 7287, pp 431-435, issn 0028-0836, 5 p.Article

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF^V600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway SuppressionHOEFLICH, Klaus P; HERTER, Sylvia; STERN, Howard et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 7, pp 3042-3051, issn 0008-5472, 10 p.Article

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in MedulloblastomaYAUCH, Robert L; DIJKGRAAF, Gerrit J. P; BAZAN, J. Fernando et al.Science (Washington, D.C.). 2009, Vol 326, Num 5952, pp 572-574, issn 0036-8075, 3 p.Article

Somatic mutations lead to an oncogenic deletion of met in lung cancerKONG-BELTRAN, Monica; SESHAGIRI, Somasekar; SEVERIN, Christophe et al.Cancer research (Baltimore). 2006, Vol 66, Num 1, pp 283-289, issn 0008-5472, 7 p.Article

Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver GenesLEE, Genee Y; HAVERTY, Peter M; DAVIS, David et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 11, pp 3114-3126, issn 0008-5472, 13 p.Article

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7WERTZ, Ingrid E; KUSAM, Saritha; BELMONT, Lisa D et al.Nature (London). 2011, Vol 471, Num 7336, pp 110-114, issn 0028-0836, 5 p.Article

Distinguishing cancer-associated missense mutations from common polymorphismsKAMINKER, Joshua S; YAN ZHANG; ZEMIN ZHANG et al.Cancer research (Baltimore). 2007, Vol 67, Num 2, pp 465-473, issn 0008-5472, 9 p.Article

Regulation of ERK3/MAPK6 expression by BRAFHOEFLICH, Klaus P; EBY, Michael T; FORREST, William F et al.International journal of oncology. 2006, Vol 29, Num 4, pp 839-849, issn 1019-6439, 11 p.Article

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. CommentaryYAUCH, Robert L; JANUARIO, Thomas; MODRUSAN, Zora et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8534-8537, issn 1078-0432, 17 p., 1Article

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerHERBST, Roy S; JOHNSON, David H; HONG, Waun K et al.Journal of clinical oncology. 2005, Vol 23, Num 11, pp 2544-2555, issn 0732-183X, 12 p.Conference Paper